Topic Highlight
Copyright ©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Jan 28, 2016; 8(3): 139-147
Published online Jan 28, 2016. doi: 10.4254/wjh.v8.i3.139
Advances in hepatitis C therapy: What is the current state - what come’s next?
Steffen Zopf, Andreas E Kremer, Markus F Neurath, Juergen Siebler
Steffen Zopf, Andreas E Kremer, Markus F Neurath, Juergen Siebler, Medical Department 1, University of Erlangen-Nuremberg, 91054 Erlangen, Germany
Author contributions: Zopf S, Kremer AE, Neurath MF and Siebler J made substantial contributions to conception and design of the manuscript; Zopf S and Kremer AE wrote the paper; Neurath MF and Siebler J critically revised the manuscript.
Conflict-of-interest statement: The authors have no conflict of interest to report.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Steffen Zopf, MD, Medical Department 1, University of Erlangen-Nuremberg, Ulmenweg 18, 91054 Erlangen, Germany. steffen.zopf@uk-erlangen.de
Telephone: +49-9131-8535000 Fax: +49-9131-8535207
Received: April 29, 2015
Peer-review started: May 8, 2015
First decision: September 8, 2015
Revised: December 15, 2015
Accepted: January 5, 2016
Article in press: January 7, 2016
Published online: January 28, 2016
Processing time: 267 Days and 0.6 Hours
Core Tip

Core tip: Treatment of chronic hepatitis C virus (HCV) infections has undergone a revolutionary change in recent years. This review highlights the current state of the art of antiviral treatment in chronic hepatitis C infections and gives an outlook for upcoming therapies. Difficult to treat populations such as patients with decompensated liver cirrhosis, HCV-human immunodeficiency virus co-infections, after liver transplantation and patients with renal impairment or on hemodialysis are highlighted.